News
GRCL
10.25
0.00%
0.00
Weekly Report: what happened at GRCL last week (0226-0301)?
Weekly Report · 03/04 09:06
Weekly Report: what happened at GRCL last week (0219-0223)?
Weekly Report · 02/26 09:06
Gracell Biotechnologies Price Target Cut to $10.25/Share From $11.00 by Stifel
Dow Jones · 02/22 14:41
Gracell Biotechnologies Cut to Hold From Buy by Stifel
Dow Jones · 02/22 14:41
Stifel Downgrades Gracell Biotechnologies to Hold, Lowers Price Target to $10.25
Benzinga · 02/22 14:31
Gracell Biotechnologies Acquisition Completed
Gracell Biotechnologies Inc. Announced the completion of its previously announced agreement to be acquired by AstraZeneca. The company is a global clinical-stage biopharmaceutical company developing innovative cell therapies for the treatment of cancer and autoimmune disease. The acquisition was structured as a merger of the two companies.
Barchart · 02/22 07:45
AstraZeneca Deal For Gracell Biotechnologies Closing Tomorrow (Includes CVR)
Seeking Alpha · 02/21 16:51
Gracell Biotechnologies receives shareholder approval for merger with AstraZeneca
Healthcare M&A Gracell Biotechnologies receives shareholder approval for merger with AstraZeneca. The China-based biopharmaceutical company and the UK-based company are expected to close the merger in February. Gracell's shareholders approved the proposed merger by 99.9% of votes cast.
Seeking Alpha · 02/20 13:09
Gracell Biotechnologies Shareholders Approve AstraZeneca Merger Agreement
Gracell Biotechnologies Inc. Shareholders voted in favor of the merger of the company with AstraZeneca in February 2024. The Company is a global clinical-stage biopharmaceutical company dedicated to developing cell therapies for the treatment of cancer and autoimmune disease. The Merger Agreement, the Plan of Merger and the Transactions were approved by approximately 99.9% of the Company's shareholders.
Benzinga · 02/20 12:55
Gracell Biotechnologies Announces Shareholders’ Approval of Merger Agreement
Gracell Biotechnologies Inc. Shareholders voted in favor of the proposal to merge with AstraZeneca on February 19, 2024. The company is a global clinical-stage biopharmaceutical company dedicated to developing cell therapies for the treatment of cancer and autoimmune disease.
Barchart · 02/20 06:45
Weekly Report: what happened at GRCL last week (0212-0216)?
Weekly Report · 02/19 09:06
Weekly Report: what happened at GRCL last week (0205-0209)?
Weekly Report · 02/12 09:06
I-Mab to divest Chinese assets amid rising geopolitical tensions
Healthcare I-Mab to divest Chinese assets amid rising geopolitical tensions. U.S. Biopharma firm to divest the company's assets and business operations in China. The move follows bipartisan legislation introduced in Congress to restrict federal funds to Chinese firms. Biotechs with roots in China have sharply underperformed over the past six months.
Seeking Alpha · 02/07 16:28
Weekly Report: what happened at GRCL last week (0129-0202)?
Weekly Report · 02/05 09:06
AstraZeneca's Q4 Earnings: Recognizing The Underrated Gem's Growth
Seeking Alpha · 02/04 14:21
Gracell Biotechnologies Receives IND Clearance For Phase 1 Trial Of GC012F In Multiple Myeloma
NASDAQ · 01/29 12:23
Weekly Report: what happened at GRCL last week (0122-0126)?
Weekly Report · 01/29 09:06
Focus On Bristol Myers, Gilead Sciences, Johnson & Johnson, Novartis: FDA To Issue Classwide Black Box Warning on CAR-T Therapies For Blood Cancer Treatment
The FDA is set to impose a classwide black box warning for all six CAR-T therapies. The agency is investigating secondary T-cell cancers arising from the use of existing CAR-Ts. The potential risk applies to all currently approved CAR-t therapies, the agency says. The affected products include those from Bristol Myers Squibb and Novartis.
Benzinga · 01/23 13:19
Weekly Report: what happened at GRCL last week (0115-0119)?
Weekly Report · 01/22 09:06
Week In Review: Lee's Pharm Signs $138M Agreement For China Rights To Heart Failure Therapy
Lee’s Pharm acquired China rights to a heart failure therapy from Windtree Therapeutics. AstraZeneca signed an investment cooperation agreement with the Taizhou National Medical High-tech Development Zone to build a new production line in China. Suzhou Adagene reported positive early data from a US Phase Ib/II trial of its cancer therapy.
Seeking Alpha · 01/21 06:55
More
Webull provides a variety of real-time GRCL stock news. You can receive the latest news about Gracell Biotechnologies Inc. through multiple platforms. This information may help you make smarter investment decisions.
About GRCL
Gracell Biotechnologies Inc is a China-based clinical-stage biopharmaceutical company focused on discovering and developing cell therapies for the treatment of cancers. The Company is primarily focused on disrupting conventional approaches to chimeric antigen receptor (CAR) thymus (T) cell therapies by leveraging its technology platforms FasTCAR and TruUCAR. With FasTCAR, the Company is able to deliver younger, less exhausted T cells for autologous cell therapies with enhanced activities and next-day manufacturing. With TruUCAR, the Company is able derive T cells from non-human leukocyte antigen (HLA)-matched healthy donors to generate allogeneic CAR-T cell therapies. The Company is levering its technology platform to develop various drug candidates, including GC012F, GC019F, GC007F, GC027 and GC007g.